Vir Biotechnology, Inc. VIR
At closeNov 10, 2026, 6:52 PM EST
After hours · Nov 10, 6:52 PM ET
- YTD
- +118.08%
- 1 year
- +144.88%
- Market cap
- 2.25B
- Revenue (ttm)
- 302.80M
- Profit margin
- -61.03%
- EPS (ttm)
- -1.18
- Shares out
- 171.27M
- Forward P/E
- -5.60
- YTD return
- +118.08%
- 1-year return
- +144.88%
- Volume
- 1.30M
- Avg volume
- 2.04M
- Open
- 13.66
- Previous close
- 13.65
- Day's range
- 13.11 – 13.74
- 52-week range
- 5.37 – 13.65
- Beta
- 1.74
- Analysts
- Strong Buy
- Price target
- 22.50 (+71.1%)
- Earnings date
- Feb 22, 2027
5D +1.41 (+12.01%)
Key statistics
- Enterprise value
- 1.97B
- PEG ratio
- 0.00
- Price / sales
- 7.44
- Price / book
- 2.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -81.92M
- Total cash
- 458.36M
- Total debt
- 90.78M
- Return on equity
- -21.84%
- Short % of float
- 9.70%
- 50-day average
- 11.09
- 200-day average
- 9.67
Analyst view
Consensus: strong buy
- Target (low)
- 17.00
- Target (mean)
- 22.50
- Target (high)
- 30.00
- Strong buy3
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 22, 2027
Expected Feb 22, 2027. Consensus EPS estimate -0.32757.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 22, 2027 | Dec 30, 2026 | -0.45 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.77042 | -0.57 | +0.20 | +26.01% |
| Aug 5, 2026 | Jun 30, 2026 | 0.3326 | 0.47 | +0.14 | +41.31% |
| May 6, 2026 | Mar 31, 2026 | -0.01 | -0.85 | -0.84 | -8,400.00% |
| Feb 23, 2026 | Dec 31, 2025 | -0.42 | -0.31 | +0.11 | +26.19% |
| Nov 5, 2025 | Sep 30, 2025 | -0.70 | -1.17 | -0.47 | -67.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 10, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Nov 9, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 9, 2026 | Needham | main | Buy | Buy |
| Nov 5, 2026 | Needham | main | Buy | Buy |
| Oct 7, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vir.bio
News
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28 
Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25 
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48 
Vir Biotechnology: Fairly Valued After Phase 3 Success? 
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target 
Vir Biotech Highlights Significant Viral Suppression in Advanced Liver Disease Study 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Reported Sunday, Vir’s Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment
Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call
Your note
Sign in to keep a note on VIR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE BACKER MARIANNE | Chief Executive Officer | Sale | Apr 5, 2026 | 1,001,260 |
| DE VERNEUIL VANINA ALEXANDRA HUARD | General Counsel | Sale | Nov 2, 2026 | 110,193 |
| EISNER MARK E | Officer | Sale | Feb 24, 2026 | 154,024 |
| HANLY ANN M | Chief Technology Officer | Sale | Feb 23, 2025 | 117,901 |
| MORE ROBERT J | Director | Stock Award(Grant) | May 26, 2026 | 558,573 |
| O'BYRNE JASON | Chief Financial Officer | Sale | Feb 23, 2026 | 162,615 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.07% | 20,678,283 | 271.92M | Jun 29, 2026 |
| Arch Venture Management, Llc | 7.41% | 12,694,163 | 166.93M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.71% | 11,495,215 | 151.16M | Jun 29, 2026 |
| SB Investment Advisers (UK) LTD | 6.39% | 10,948,093 | 143.97M | Jun 29, 2026 |
| State Street Corporation | 5.82% | 9,964,151 | 131.03M | Jun 29, 2026 |
| GSK plc | 4.99% | 8,550,954 | 112.45M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.83% | 4,846,948 | 63.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.06% | 3,533,092 | 46.46M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.03% | 3,476,669 | 45.72M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.49% | 2,546,144 | 33.48M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.17% | 1,996,625 | 26.26M | Jun 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 1.03% | 1,762,412 | 23.18M | Jun 29, 2026 |